Cisplatin. Current Status and New Developments

519 Pages·1980·20.91 MB·English

by  Archie W. Prestayko (Eds.)

C I S P L A T IN
CURRENT STATUS AND NEW DEVELOPMENTS
Edited by
Archie W. Prestayko Stanley T. Crooke
Bristol Laboratories Bristol Laboratories
Syracuse, New York Syracuse, New York
Baylor College of Medicine Baylor College of Medicine
Houston, Texas Houston, Texas
Upstate Medical Center
Syracuse, New York
Stephen K. Carter
Northern California Cancer Program
Palo Alto, California
Stanford University Medical Center
Stanford, California
University of California
San Francisco, California
Assisted by
Nancy A. Alder
Syracuse, New York
ACADEMIC PRESS
A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York London Toronto Sydney San Francisco 1980
COPYRIGHT © 1980, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.
NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.
ACADEMIC PRESS, INC.
Ill Fifth Avenue, New York, New York 10003
United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1 7DX
Library of Congress Cataloging in Publication Data
Main entry under title:
Cisplatin, current status and new developments.
Papers presented at a symposium sponsored by the
University of Alabama in Birmingham Comprehensive
Cancer Center and the Bristol Laboratories, Syracuse,
Ν. Y., and held Sept. 27-28,1979, in Atlanta, Ga.
1. Cisplatin-Congresses. 2. Cancer-Chemotherapy
-Congresses. I. Prestayko, Archie W. II. Crooke,
Stanley Τ. III. Carter, Stephen Κ. IV. University
of Alabama in Birmingham. Comprehensive Cancer Center.
V. Bristol-Myers Company. Bristol Laboratories.
[DNLM: 1. Neoplasms-Drug therapy-Congresses.
2. Platinum-Therapeutic use-Congresses. QV290 C579
1979]
RC271.C55C57 616.99'4061 80-12220
ISBN 0-12-565050-7
PRINTED IN THE UNITED STATES OF AMERICA
80 81 82 83 9 8 7 6 5 4 3 2 1
CONTRIBUTORS
Numbers in parentheses indicate the pages on which authors' contributions begin.
SURINDER Ę. AGGARWAL (ş 9), Department of Zoology, Michigan State Uni­
versity, East Lansing, Michigan 48824
DAVID S. ALBERTS (393), Section of Hematology-Oncology, Department of
Internal Medicine, College of Medicine, University of Arizona, Tucson,
Arizona 85724
SUSAN T. ARNOLD (237), Laboratory of Toxicology, Division of Cancer Treat­
ment, National Cancer Institute, Bethesda, Maryland 20205
LAURENCE H. BAKER (403), Professor of Oncology, Wayne State University,
Detroit, Michigan 48202
BARTHEL BARLOGIE (37), Department of Developmental Therapeutics, The
University of Texas System Cancer Center, M. D. Anderson Hospital and
Tumor Institute, 6723 Bertner Drive, Houston, Texas 77025
ROBERT S. BENJAMIN (495), Department of Developmental Therapeutics,
M. D. Anderson Hospital and Tumor Institute, University of Texas Sys­
tem Cancer Center, Houston, Texas 77030
JOHN-PIERRE BERGERAT (37), Clinique des Maladies du Sang, Hospices
civils de Strasbourg, 1 place de IHopital, 67000 Strasbourg, France
RAKESH BHUTANI (431), Section of Medical Oncology, Department of Inter­
nal Medicine, Veterans Administration Medical Center, Boston, Massachu­
setts 02130
WERNER C. BIERBAUM (329), Universitatsklinikum der Gesamthochschule
Innere Klinik and Poliklinik (Tumorforschung), 4300 Essen 1, Hufeland­
strasse 55, Federal Republic of Germany
JOHN BLESSING (411), Gynecologic Oncology Group Statistical Office, Ros-
well Park Memorial Institute, 666 Elm Street, Buffalo, New York 14203
WILLIAM T. BRADNER (171, 227), Antitumor Biology Department, Bristol
Laboratories, Division of Bristol-Myers Company, Syracuse, New York
13201
HOWARD W. BRUCKNER (383), Department of Neoplastic Diseases, Mount
Sinai School of Medicine of the City University of New York, Fifth
Avenue and East 100 Street, New York, New York 10029
vii
viii Contributors
JOSEPH H. BURCHENAL (113), Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, New York, New York 10021
DIONISIO Â. CALVO III (495), Department of Developmental Therapeutics,
Ě. D. Anderson Hospital and Tumor Institute, University of Texas Sys­
tem Cancer Center, Houston, Texas 77030
BRENDA CAPARROS (465), Department of Pediatrics, Memorial Sloan-
Kettering Cancer Center, 1275 York Avenue, New York, New York 10021
STEPHEN K. CARTER (511), Northern California Cancer Program, P. O. Box
10144, Palo Alto, California 94303
SYLVIA CLARKE (193), Department of Biochemical Pharmacology, Institute
of Cancer Research, Belmont, Surrey, England
MICHAEL J. CLEARE (149), Chemical Operations Research, Johnson Matthey
Research Centre, Blounts Court, Sonning Common, Reading, Berkshire,
England
HUGH McD. CLINK (193), Department of Haematology, Royal Marsden Hospi­
tal, Belmont, Surrey, England
CARMEL J. COHEN (383), Department of Neoplastic Diseases, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
ROBERT L. COMIS (485), Chief, Section of Oncology, SUNY Upstate Medical
Center, Syracuse, New York 13210
PETER CORRY {31), Department of Physics, The University of Texas System
Cancer Center, M. D. Anderson Hospital, 6723 Bertner Drive, Houston,
Texas 77025
STANLEY T. CROOKE (213, 249), Bristol Laboratories, Department of Re­
search and Development, Syracuse, New York 13201; Department of Phar­
macology, Baylor College of Medicine, Houston, Texas 77025; Department
of Pharmacology, SUNY Upstate Medical Center, Syracuse, New York
13210
YERACH DASKAL (249), Department of Pharmacology, Baylor College of
Medicine, Houston, Texas 77025
PHILIP DiSALA (411), Department of Obstetrics and Gynecology, University of
California at Irvine, Irvine, California 92717
EVAN B. DOUPLE (125), Radiobiology Laboratories oftheNorris Cotton Can­
cer Center, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire
03755
GARY J. DOYLE (227), Department of Toxicology, Bristol Laboratories, Divi­
sion of Bristol-Myers Company, Syracuse, New York 13201
BENJAMIN DREWINKO (37), Department of Laboratory Medicine, The Uni­
versity of Texas System Cancer Center, M. D. Anderson Hospital, 6723
Bertner Drive, Houston, Texas 77025
JOHN R. DURANT (317), Director, Comprehensive Cancer Center, University
of Alabama in Birmingham, University Station, Birmingham, Alabama
35294
Contributors ix
LAWRENCE Ç. EINHORN (323), Department of Medicine, Indiana University
Medical Center and the Indianapolis Veteran's Administration Hospital,
Indianapolis, Indiana 46223
DAVID ELSON (AAS), Department of Medicine, Division of Oncology, Univer­
sity of Texas Health Science Center at San Antonio, San Antonio, Texas
78284
RONALD H. ERLICH (305), Product Development Research, Bristol Labora­
tories, Division of Bristol-Myers Company, Syracuse, New York 13201
WILLIAM E. EVANS (477), Department of Pharmacy, St. Jude Children's Re­
search Hospital, 332 N. Lauderdale, Memphis, Tennessee 38101
HADRIAN N. A. FRAVAL (57), Institute of,Cancer Research, Royal Cancer
Hospital, Pollards Wood Research Station, Nightingales Lane, Chalfont
St. Giles, Buckinghamshire, United Kingdom HP8 4S
MICHAEL A. FRIEDMAN (459), University of California, Department of Medi­
cine, Cancer Research Institute, San Francisco, California 94143
GLEN GALE (113), Veterans Administration Hospital, 109 Bee Street, Charles­
ton, South Carolina 29403
JUDITH GOLDBERG (383), Department of Neoplastic Diseases, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
ALPHONSE P. GRANATEK (305), Research and Development, Bristol Labora­
tories, Division of Bristol-Myers Company, Syracuse, New York 13201
ALEXANDER A. GREEN (477),Department of Hematology/Oncology, St. Jude
Children's Research Hospital, 332 N. Lauderdale, Memphis, Tennessee
38101
EZRA M. GREENSPAN (383), Department of Neoplastic Diseases, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
ANTHONY M. GUARINO (237), Laboratory of Toxicology, Division of Cancer
Treatment, National Cancer Institute, Bethesda, Maryland 20205
SAUL B. GUSBERG (383), Department of Neoplastic Diseases, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
MANUEL GUTIERREZ (465), Clinical Cancer Research, Bristol Laboratories,
Division of Bristol-Myers Company, Syracuse, New York 13201
JONAS A. GYLYS (227), Department of Pharmacology, Bristol Laboratories,
Division of Bristol-Myers Company, Syracuse, New York 13201
MILES P. HACKER (237),Midwest Research Institute, 425 Volker Blvd., Kansas
City, Missouri 64110
KENNETH R. HARRAP (193), Department of Biochemical Pharmacology, In­
stitute of Cancer Research, Belmont, Surrey, England
F. ANN HAYES (477), St. Jude Children's Research Hospital, 332 N. Lauder­
dale, Memphis, Tennesse 38101
χ Contributors
DERIC R. HEPBURN (149), Chemical Operations Research, Johnson Matthey
Research Centre, Blounts Court, Sonning Common, Reading, Berkshire,
England
MARKUS HIGI (329), Universitätsklinikum, der Gesamthochschule Innere Klinik
and Poliklinik (Tumorforschung) 4300 Essen 1, Hufelandstrasse 55, Fed­
eral Republic of Germany
ROBERT D. HILGERS (393), University of New Mexico Cancer Research Treat­
ment Center, Albuquerque, New Mexico 87131
JAMES F. HOLLAND (383), Department of Neoplastic Disease, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
HOWARD HOMESLEY (411), Department of Obstetrics and Gynecology,
Bowman-Gray School of Medicine of Wake Forest University, Winston-
Salem, North Carolina 27103
WAUN KI HONG (431), Section of Medical Oncology, Department of Internal
Medicine, Veterans Administration Medical Center, Boston, Massachusetts
02130
CATHRYN B. HOWARTH (477), St. Jude Children's Research Hospital, 332 Í
Lauderdale, Memphis, Tennessee 38101
JAMES B. HUFTALEN (171,227), Antitumor Biology Department, Bristol La­
boratories, Division of Bristol-Myers Company, Syracuse, New York 13201
PAUL C. HYDES (149), Chemical Operations Research, Johnson Matthey Re­
search Centre, Blounts Court, Sonning Common, Reading, Berkshire,
England
CHARLOTTE JACOBS (423), Department of Medicine, Stanford University
School of Medicine, Stanford, California 94305
MERVYN JONES (193), Department of Biochemical Pharmacology, Institute
of Cancer Research, Belmont, Surrey, England
HERBERT JUERGENS (465), Kinderklinic Der Universität Dusseldorf Mooren-
str. 5, 4000 Dusseldorf, Germany
KURT W. KOHN (21), Laboratory of Molecular Pharmacology, Division of Can­
cer Treatment, National Cancer Institute, Bethesda, Maryland 20205
LEO LAG ASSE (411), Department of Obstetrics and Gynecology, University of
California, Los Angeles, Los Angeles, California 90024
LINDA LOKYS (113), Memorial Sloan-Kettering Cancer Center, 1275 York
Avenue, New York, New York 10021
DAVID F. LONG (285), Department of Pharmaceutical Chemistry, School of
Pharmacy, University of Kansas, Lawrence, Kansas 66044
BERNARD W. MALERBI (149), Chemical Operations Research, Johnson Mat­
they Research Centre, Blounts Court, Sonning Common, Reading, Berk­
shire, England
RANDALL C. MANAKA (211), Radiopharmacy Program, University of Southern
California, School of Pharmacy, Los Angeles, California 90007
Contributors xi
FRANK MANTZ (393), University of Kansas School of Medicine, Kansas City,
Kansas 66103
ELIO P. MARIANI (305), Product Development Research, Bristol Laboratories,
Division of Bristol-Myers Company, Syracuse, New York 13201
PIERRE W. MARTUVIBEAU (393), Cleveland Clinic Foundation, Cleveland,
Ohio 44106
NANCY MASON (393), University of Arizona Cancer Center, Tucson, Arizona
85721
STEVEN B. MASTERS (345), Department of Urology, University of Tennessee
Center for the Health Sciences, and Memphis Veterans Administration
Hospital, Memphis, Tennessee 38104
GEORGES MATHÉ (517), Institute of Cancerology and Immunogenetics, Hos­
pital Paul-Brousse, Villejuif France
GIORA M. MAVLIGIT (495), Department of Developmental Therapeutics, M. D.
Anderson Hospital, and Tumor Institute, University of Texas System Can­
cer Center, Houston, Texas 77030
CLAUDE MERRIN (375), Urologie Oncologist, Swedish Covenant Hospital, Chi­
cago, Illinois 60625
DAVID S. MILLER (237), Mount Desert Island Biological Laboratory, Salsbury
Cove, Maine 04672
BERNARD C. V. MITCHLEY (193), Department of Biochemical Pharmacology,
Institute of Cancer Research, Belmont, Surrey, England
SEYMOUR MONG (213), Department of Pharmacology, Baylor College of Med­
icine, Houston, Texas 77025
THOMAS E.MOON (393), University of Arizona Cancer Center, Tucson, Arizona
85721
DESPINA MOURATIDOU (329), Universitatsklinikum der Genamthochschule
Innere Klinik and Poliklinik (Tumorforschung) 4300 Essen 1, Hufeland­
strasse 55, Federal Republic of Germany
FRANCO Ě. MUGGIA (517), Formerly at Cancer Therapy Evaluation Program,
National Cancer Institute, Bethesda, Maryland 20205. Presently at Division
of Oncology, New York University Medical Center, New York, New York
10016
WILLIAM M. MURPHY (345), Department of Pathology, University of Tennes­
see Center for the Health Sciences, and Memphis Veterans Administration
Hospital, Memphis, Tennessee 38104
NORBERT NIEDERLE (329), Universitatsklinikum der Gesamthochschule In­
nere Klinik and Poliklinik (Tumorforschung) 4300 Essen 1, Hufelandstrasse
55, Federal Republic of Germany
ANITA NIRENBERG (465), Department of Nursing/Pediatrics, Memorial Sloan-
Kettering Cancer Center, 1275 York Avenue, New York, New York 10021
ROBERT OTOOLE (393), Ohio State University School of Medicine, Columbus,
Ohio 43210
xii Contributors
YEHUDA Ć. PATT (495), Department of Developmental Therapeutics, M. D.
Anderson Hospital and Tumor Institute, University of Texas System Can­
cer Center, Houston, Texas 77030
CHARLES B. PRATT {All), Department of Clinical Therapeutics, St. Jude Chil­
dren's Research Hospital, 332 N. Lauderdale, Memphis, Tennessee 38101
ARCHIE W. PRESTAYKO (1, 213, 249), Bristol Laboratories, Syracuse, New
York 13201; Department of Pharmacology, Baylor College of Medicine,
Houston, Texas 77025
C. RAMACHANDRAN {19), Department of Biochemistry, Faculty of Science,
The Australian National University, Canberra, A.CT. Australia 2600
ARNOLD J. REPTA (285), Department of Pharmaceutical Chemistry, School of
Pharmacy, University of Kansas, Lawrence, Kansas 66044
PATRICIA RIBAUD (517), Institute of Cancerology and Immunogenetics, Hos­
pital Paul-Brousse, Villejuif France
ROBERT C. RICHMOND (125), Radiobiology Laboratories of the Nonis Cot­
ton Cancer Center, Dartmouth-Hitchcock Medical Center, Hanover, New
Hampshire 03755
SAUL RIVKIN (393), Tumor Institute of Swedish Hospital Medical Center,
Seattle, Washington 98104
JOHN J. ROBERTS (57), Institute of Cancer Research, Royal Cancer Hospital,
Pollards Wood Research Station, Nightingales Lane, Chalfont St. Giles,
Buckinghamshire, United Kingdom HP8 4S
WILLIAM C. ROSE (171), Antitumor Biology, Bristol Laboratories, Division of
Bristol-Myers Company, Syracuse, New York 13201
GERALD ROSEN (465), Departments of Pediatrics and Medicine (Solid Tumor
Service), Memorial Sloan-Kettering Cancer Center, 1275 York Avenue,
New York, New York 10021
BARNETT ROSENBERG (9), Department of Biophysics, Michigan State Uni­
versity, East Lansing, Michigan 48824
MAX E. SCHEULEN (329), Universitatsklinikum der Gesamthochschule Innere
Klinik and Poliklinik (TumorforschungJ 4300 Essen 1, Hufelandstrasse 55,
Federal Republic of Germany
RUDOLF Â. SCHILCHER (329), Universitatsklinikum der Gesamthochschule
Innere Klinik and Poliklinik (Tumorforschung) 4300 Essen 1, Hufeland­
strasse 55, Federal Republic of Germany
CARL G. SCHMIDT (329), Universitatsklinikum der Gesamthochschule Innere
Klinik and Poliklinik (Tumorforschung) 4300 Essen 1, Hufelandstrasse 55,
Federal Republic of Germany
JOHN Ĺ. SCHURIG (227), Department of Pharmacology, Bristol Laboratories,
Division of Bristol-Myers Company, Syracuse, New York 13201
SIEGFRIED SEEBER (329), Universitatsklinikum der Gesamthochschule Innere
Klinik and Poliklinik (Tumorforschung) 4300 Essen 1, Hufelandstrasse 55,
Federal Republic of Germany
Contributors xiii
NEIL SENZER (477), Pediatrics, St. Jude Children's Research Hospital, 332Í
Lauderdale, Memphis, Tennessee 38101
STANLEY M. SHAPSHAY (431), Department of Otolaryngology, Veterans Ad­
ministration Medical Center, and Boston University Medical Center, Bos­
ton, Massachusetts 02215
HUGH SHINGLETON (411), Department of Obstetrics and Gynecology, Uni­
versity of Alabama School of Medicine, Birmingham, Alabama 35294
MARK S. SOLOWAY (345), Department of Urology, University of Tennessee
Center for the Health Sciences, and Memphis Veterans Administration
Hospital, Memphis, Tennessee 38104
BRUCE J. SOUTHARD (305), Product Development Research, Bristol Labora­
tories, Division of Bristol-Myers Company, Syracuse, New York 13201
STEPHEN SPARROW (193), Laboratory Animal Centre, Medical Research
Council Carshalton, Surrey, England
RONALD L. STEPHENS (393), University of Kansas School of Medicine, Kan­
sas City, Kansas 66103
STUART STRONG (431), Department of Otolaryngology, Boston University,
Boston, Massachusetts 02215
CHARLOTTE TAN (465), Department of Pediatrics, Memorial Sloan-Kettering
Cancer Center, 1275 York Avenue, New York, New York 10021
J. TATE THIGPEN (411), Departments of Medicine, Obstetrics and Gynecology,
University of Mississippi School of Medicine, Jackson, Mississippi 39216
JOHN TURKEVICH (113), Department of Chemistry, Princeton University,
Princeton, New Jersey 08540
MARY A. URBANEK (237), Bat telle Toxicology Program Office, 8330 Old
Court House Road, Vienna, Virginia 22180
ANN VEASEY (193), Department of Haematology, Royal Marsden Hospital,
Belmont, Surrey, England
DANIEL D. VON HOFF (445), Department of Medicine, Division of Oncology,
University of Texas Health Science Center at San Antonio, San Antonio,
Texas 78284
ROBERT C. WALLACH (383), Department of Neoplastic Diseases, Mount Sinai
School of Medicine of the City University of New York, Fifth Avenue and
East 100 Street, New York, New York 10029
MICHAEL W. WHITEHOUSE (79), Department of Experimental Pathology,
John Curtin School of Medical Research, The Australian National Univer­
sity, Canberra, A.C.T. Australia, 2600
C. RAY WILKINSON (193), Department of Biochemical Pharmacology, Institute
of Cancer Research, Belmont, Surrey, England
STEPHEN D. WILLIAMS (323), Department of Medicine, Indiana University
Medical Center and the Indianapolis Veteran's Administration Hospital,
Indianapolis, Indiana 46223
xiv Contributors
WALTER WOLF (271), Radiopharmacy Program, University of Southern Cali­
fornia, School of Pharmacy, Los Angeles, California 90007
MARY K. WOLPERT-DeFILIPPES (183, 237, 517), Drug Evaluation Branch,
Developmental Therapeutics Program, National Cancer Institute, Bethesda,
Maryland 20205
JOHN T. WOOLEVER (305), Product Development Research, Bristol Labora­
tories, Division of Bristol-Myers Company, Syracuse, New York 13201
ALAN YAGODA (361), Department of Medicine, Memorial Sloan-Kettering
Cancer Center, 1275 York Avenue, New York, New York 10021
LEONARD A. ZWELLING (21), Laboratory of Molecular Pharmacology, Divi­
sion of Cancer Treatment, National Cancer Institute, National Institutes
of Health, Bethesda, Maryland 20205